{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zheng Y"],"funding":["This work was supported by Sinovac Biotech Co., Ltd.."],"pagination":["254"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8879689"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(2)"],"pubmed_abstract":["Background
The Sabin-strain-based inactivated poliovirus vaccine (sIPV) plays an important role in poliomyelitis eradication in developing countries. As part of the phase III clinical development program, this study aimed to evaluate the safety, immunogenicity and lot-to-lot consistency of the sIPV in 2-month-old infants.Method
We conducted a phase III, randomized, double-blind, positive-controlled trial in which 1300 healthy infants were randomly assigned to four groups in a 1:1:1:1 ratio to receive one of the three lots of the sIPV or the control IPV at 2, 3 and 4 months of age. Serum samples were collected before the first dose and 30 days after the third dose of vaccination to assess the immunogenicity. Solicited local and systemic reactions were recorded within 7 days "],"journal":["Vaccines"],"pubmed_title":["Safety, Immunogenicity and Lot-to-Lot Consistency of Sabin-Strain Inactivated Poliovirus Vaccine in 2-Month-Old Infants: A Double-Blind, Randomized Phase III Trial."],"pmcid":["PMC8879689"],"funding_grant_id":["None"],"pubmed_authors":["Xu L","Zheng Y","Qian D","Lei J","Li C","Han W","Wang J","Jiang Y","Liu X","Zou Y","Jiang Z","Li X","Ying Z","Jiang D","Zhu T"],"additional_accession":[]},"is_claimable":false,"name":"Safety, Immunogenicity and Lot-to-Lot Consistency of Sabin-Strain Inactivated Poliovirus Vaccine in 2-Month-Old Infants: A Double-Blind, Randomized Phase III Trial.","description":"Background
The Sabin-strain-based inactivated poliovirus vaccine (sIPV) plays an important role in poliomyelitis eradication in developing countries. As part of the phase III clinical development program, this study aimed to evaluate the safety, immunogenicity and lot-to-lot consistency of the sIPV in 2-month-old infants.Method
We conducted a phase III, randomized, double-blind, positive-controlled trial in which 1300 healthy infants were randomly assigned to four groups in a 1:1:1:1 ratio to receive one of the three lots of the sIPV or the control IPV at 2, 3 and 4 months of age. Serum samples were collected before the first dose and 30 days after the third dose of vaccination to assess the immunogenicity. Solicited local and systemic reactions were recorded within 7 days ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-04-08T17:24:24.526Z","creation":"2025-04-19T22:36:05.266Z"},"accession":"S-EPMC8879689","cross_references":{"pubmed":["35214712"],"doi":["10.3390/vaccines10020254"]}}